Глюкокортикостероиды при внебольничной пневмонии (казнить нельзя помиловать)

1. Сёмаш Н.А., Белевский А.С., Вязьменова Н.И. Возможности неантибактериальной терапии внебольничной пневмонии. Пульмонология. 2012;(2):99-101 [Syomash NA, Belevsky AS, Vyaz'menova NI. Possibilities of non-antibacterial therapy of community-acquired pneumonia. Pulmonologiya. 2012;(2):99-101 (in Russian)].
DOI:10.18093/0869-0189-2012-0-2-99-101
2. Крюков Е.В., Зайцев А.А., Чернецов В.А., и др. Современные возможности и ограничения адъювантной терапии внебольничной пневмонии. Медицинский вестник МВД. 2017;86(1):32-5 [Kryukov YeV, Zaitsev AA, Chernetsov VA, et al. Modern resources and limitations of adjunctive therapyof community-acquired pneumonia. MIA Medical Bulletin. 2017;86(1):32-5 (in Russian)].
3. Авдеев С.Н., Адамян Л.В., Баранов А.А., и др. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.2022). Москва. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/ВМР_COVID-19_V17.p.... Ссылка активна на 03.09.2023 [Avdeev SN, Adamian LV, Baranov AA, et al. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiia 17 (14.12.2022). Moscow. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/ВМР_COVID-19_V17.p.... Accessed: 03.09.2023 (in Russian)].
4. Зайцев А.А. Письмо в редакцию. Клиническая микробиология и антимикробная химиотерапия. 2020;22(2):84-6 [Zaitsev AA. Letter to editors. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):84-6 (in Russian)]. DOI:10.36488/cmac.2020.2.84-86
5. Зайцев А.А., Чернов С.А., Стец В.В., и др. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре. Методические рекомендации. Consilium Medicum. 2020;22(11):91-7 [Zaitsev AA, Chernov SA, Stets VV, et al. Algorithms for the management of patients with a new coronavirus COVID-19 infection in a hospital. Guidelines. Consilium Medicum. 2020;22(11):91-7 (in Russian)]. DOI:10.26442/20751753.2020.11.200520
6. Wagner HN, Bennet IL, Lasagna L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp.
1956;98(3):197-215.
7. Hedlund J. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short- and long-term prognosis. Scand J Infect Dis Suppl. 1995;97:1-60.
PMID: 8584866
8. Rodrigues J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med. 1992;93(1):29-34.
DOI:10.1016/0002-9343(92)90676-3
9. Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis. 1985;17(4):377-86. DOI:10.3109/13813458509058778
10. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993;104(2):389-92. DOI:10.1378/chest.104.2.389
11. Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008;32(2):259-64. DOI:10.1183/09031936.00154107
12. Confalonieri М, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-8. DOI:10.1164/rccm.200406-808oc
13. Confalonieri М, Trevisan R. Prolonged infusion of hydrocortisone in patients with severe community acquired pneumonia. Recenti Prog Med. 2006;97(1):32-6 [Article in Italian].
14. Agustí C, Rañó A, Filella X, González J, Moreno A, Xaubet A, Torres A. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123(2):488-98. DOI:10.1378/chest.123.2.488
15. Keh D, Boenhke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of „low-dose“ hydrocortisone in septic shock: a double blind, randomised, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167(4):512-20. DOI:10.1164/rccm.200205-446oc
16. Gorman SK, Slavik RS, Marin J. Corticosteroid Treatment of Severe Community-Acquired Pneumonia. Ann Pharmacothe. 2007;41(7):1233-7. DOI:10.1345/aph.1h660
17. Siempos I, Vardakas K, Kopterides P, Falagas M. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62(4):661-8. DOI:10.1093/jac/dkn283
18. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511-8. DOI:10.1016/s0140-6736(14)62447-8
19. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677-86. DOI:10.1001/jama.2015.88
20. Ceccato A, Cilloniz C, Ranzani O, et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS One. 2017;12(6):e0178022. DOI:10.1371/journal.pone.0178022
21. Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis. 2016;8(3):162-71. DOI:10.21037/jtd.2016.02.43
22. Siemieniuk R, Meade M, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519-28. DOI:10.7326/m15-0715
23. Chen LP, Chen JH, Chen Y, et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. World J Emerg Med. 2015;6(3):172-8. DOI:10.5847/wjem.j.1920-8642.2015.03.002
24. Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. Medicine (Baltimore). Medicine. 2019;98(26):e16239. DOI:10.1097/md.0000000000016239
25. Meduri G, Shih M-C, Bridges L, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48(8):1009-23. DOI:10.1007/s00134-022-06684-3
26. Saleem N, Kulkarni A, Snow TAC, et al. Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2023;163(3):484-97. DOI:10.1016/j.chest.2022.08.2229
27. Dequin PF, Meziani F, Quenot JP, et al; CRICS-TriGGERSep Network. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023;388(21):1931-41. DOI:10.1056/nejmoa2215145
28. McHardy VU, Schonell ME. Ampicillin Dosage and Use of Prednisolone in Treatment of Pneumonia: Co-operative Controlled Trial. Br Med J. 1972;4(5840):569-73. DOI:10.1136/bmj.4.5840.569
29. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2006;55:91-9.
30. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185(5):249-55. DOI:10.1007/s00408-007-9020-3
31. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-82. DOI:10.1164/rccm.200905-0808oc
32. Sabry N, Omar E. Corticosteroids and ICU course of community-acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011;2:73-81. DOI:10.4236/pp.2011.22009
33. Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96. DOI:10.1186/cc10103
34. Meijvis S, Hardeman H, Remmelts H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-30. DOI:10.1016/s0140-6736(11)60607-7
35. Nafae R, Ragab M, Amany F, Rashed S. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2013;62(3):439-45. DOI:10.1016/j.ejcdt.2013.03.009
36. Lloyd M, Karahalios A, Janus E, et al; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019;179(8):1052-60. DOI:10.1001/jamainternmed.2019.1438
37. Wittermans E, Vestjens S, Spoorenberg S, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J. 2021;58(2):2002535. DOI:10.1183/13993003.02535-2020
38. Harris L, Crannage A. Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature J Pharm Technol. 2021;37(3):152-60. DOI:10.1177/8755122521995587
39. Metlay J, Waterer G, Long A, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI:10.1164/rccm.201908-1581st
40. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-32. DOI:10.1007/s00134-023-07033-8
41. Авдеев С.Н., Дехнич А.В., Зайцев А.А., и др. Внебольничная пневмония: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):295-355 [Avdeev SN, Dekhnich AV, Zaytsev AA, et al. Federal guidelines on diagnosis and treatment of community-acquired pneumonia. Pulmonologiya. 2022;32(3):295-355 (in Russian)]. DOI:10.18093/0869-0189-2022-32-3-295-355
42. Кучмин А.Н., Акимкин В.Г., Синопальников А.И., и др. Диагностика, лечение и профилактика внебольничной пневмонии у военнослужащих МО РФ. Методические указания. Москва, 2010. Режим доступа: https://studopedia.org/10-125692.html. Ссылка активна на 12.09.2023 [Kuchmin AN, Akimkin VG, Sinopal'nikov AI, et al. Diagnostika, lechenie i profilaktika vnebol'nichnoi pnevmonii u voennosluzhashchikh MO RF. Metodicheskie ukazaniia. Moscwa, 2010. Available at: https://studopedia.org/10-125692.html. Accessed: 12.09.2023 (in Russian)].
43. Авдеев С.Н., Белобородов В.Б., Белоцерковский Б.З., и др. Тяжелая внебольничная пневмония у взрослых. Клинические рекомендации Федерации анестезиологов и реаниматологов России. Анестезиология и реаниматология (Медиа Сфера). 2022;(1):6-35 [Avdeev SN, Beloborodov VB, Belotserkovskiy BZ, et al. Severe community-acquired pneumonia in adults. Clinical recommendations from Russian Federation of Anaesthesiologists and Reanimatologists. Russian Journal of Anesthesiology and Reanimatology.
2022;(1):6-35 (in Russian)]. DOI:10.17116/anaesthesiology20220116

________________________________________________

1. Syomash NA, Belevsky AS, Vyaz'menova NI. Possibilities of non-antibacterial therapy of community-acquired pneumonia. Pulmonologiya. 2012;(2):99-101 (in Russian). DOI:10.18093/0869-0189-2012-0-2-99-101
2. Kryukov YeV, Zaitsev AA, Chernetsov VA, et al. Modern resources and limitations of adjunctive therapyof community-acquired pneumonia. MIA Medical Bulletin. 2017;86(1):32-5 (in Russian).
3. Avdeev SN, Adamian LV, Baranov AA, et al. Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Versiia 17 (14.12.2022). Moscow. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/ВМР_COVID-19_V17.p.... Accessed: 03.09.2023 (in Russian).
4. Zaitsev AA. Letter to editors. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(2):84-6 (in Russian). DOI:10.36488/cmac.2020.2.84-86
5. Zaitsev AA, Chernov SA, Stets VV, et al. Algorithms for the management of patients with a new coronavirus COVID-19 infection in a hospital. Guidelines. Consilium Medicum. 2020;22(11):91-7 (in Russian). DOI:10.26442/20751753.2020.11.200520
6. Wagner HN, Bennet IL, Lasagna L, et al. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp.
1956;98(3):197-215.
7. Hedlund J. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short- and long-term prognosis. Scand J Infect Dis Suppl. 1995;97:1-60.
PMID: 8584866
8. Rodrigues J, Niederman MS, Fein AM, Pai PB. Nonresolving pneumonia in steroid-treated patients with obstructive lung disease. Am J Med. 1992;93(1):29-34.
DOI:10.1016/0002-9343(92)90676-3
9. Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis. 1985;17(4):377-86. DOI:10.3109/13813458509058778
10. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993;104(2):389-92. DOI:10.1378/chest.104.2.389
11. Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008;32(2):259-64. DOI:10.1183/09031936.00154107
12. Confalonieri М, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-8. DOI:10.1164/rccm.200406-808oc
13. Confalonieri М, Trevisan R. Prolonged infusion of hydrocortisone in patients with severe community acquired pneumonia. Recenti Prog Med. 2006;97(1):32-6 [Article in Italian].
14. Agustí C, Rañó A, Filella X, González J, Moreno A, Xaubet A, Torres A. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123(2):488-98. DOI:10.1378/chest.123.2.488
15. Keh D, Boenhke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of „low-dose“ hydrocortisone in septic shock: a double blind, randomised, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167(4):512-20. DOI:10.1164/rccm.200205-446oc
16. Gorman SK, Slavik RS, Marin J. Corticosteroid Treatment of Severe Community-Acquired Pneumonia. Ann Pharmacothe. 2007;41(7):1233-7. DOI:10.1345/aph.1h660
17. Siempos I, Vardakas K, Kopterides P, Falagas M. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother. 2008;62(4):661-8. DOI:10.1093/jac/dkn283
18. Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511-8. DOI:10.1016/s0140-6736(14)62447-8
19. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677-86. DOI:10.1001/jama.2015.88
20. Ceccato A, Cilloniz C, Ranzani O, et al. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. PLoS One. 2017;12(6):e0178022. DOI:10.1371/journal.pone.0178022
21. Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis. 2016;8(3):162-71. DOI:10.21037/jtd.2016.02.43
22. Siemieniuk R, Meade M, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519-28. DOI:10.7326/m15-0715
23. Chen LP, Chen JH, Chen Y, et al. Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: A meta-analysis of randomized controlled trials. World J Emerg Med. 2015;6(3):172-8. DOI:10.5847/wjem.j.1920-8642.2015.03.002
24. Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis. Medicine (Baltimore). Medicine. 2019;98(26):e16239. DOI:10.1097/md.0000000000016239
25. Meduri G, Shih M-C, Bridges L, et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022;48(8):1009-23. DOI:10.1007/s00134-022-06684-3
26. Saleem N, Kulkarni A, Snow TAC, et al. Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2023;163(3):484-97. DOI:10.1016/j.chest.2022.08.2229
27. Dequin PF, Meziani F, Quenot JP, et al; CRICS-TriGGERSep Network. Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023;388(21):1931-41. DOI:10.1056/nejmoa2215145
28. McHardy VU, Schonell ME. Ampicillin Dosage and Use of Prednisolone in Treatment of Pneumonia: Co-operative Controlled Trial. Br Med J. 1972;4(5840):569-73. DOI:10.1136/bmj.4.5840.569
29. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2006;55:91-9.
30. Mikami K, Suzuki M, Kitagawa H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185(5):249-55. DOI:10.1007/s00408-007-9020-3
31. Snijders D, Daniels JM, de Graaff CS, et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-82. DOI:10.1164/rccm.200905-0808oc
32. Sabry N, Omar E. Corticosteroids and ICU course of community-acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011;2:73-81. DOI:10.4236/pp.2011.22009
33. Fernández-Serrano S, Dorca J, Garcia-Vidal C, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96. DOI:10.1186/cc10103
34. Meijvis S, Hardeman H, Remmelts H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-30. DOI:10.1016/s0140-6736(11)60607-7
35. Nafae R, Ragab M, Amany F, Rashed S. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egypt J Chest Dis Tuberc. 2013;62(3):439-45. DOI:10.1016/j.ejcdt.2013.03.009
36. Lloyd M, Karahalios A, Janus E, et al; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019;179(8):1052-60. DOI:10.1001/jamainternmed.2019.1438
37. Wittermans E, Vestjens S, Spoorenberg S, et al. Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Eur Respir J. 2021;58(2):2002535. DOI:10.1183/13993003.02535-2020
38. Harris L, Crannage A. Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature J Pharm Technol. 2021;37(3):152-60. DOI:10.1177/8755122521995587
39. Metlay J, Waterer G, Long A, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. DOI:10.1164/rccm.201908-1581st
40. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-32. DOI:10.1007/s00134-023-07033-8
41. Avdeev SN, Dekhnich AV, Zaytsev AA, et al. Federal guidelines on diagnosis and treatment of community-acquired pneumonia. Pulmonologiya. 2022;32(3):295-355 (in Russian). DOI:10.18093/0869-0189-2022-32-3-295-355
42. Kuchmin AN, Akimkin VG, Sinopal'nikov AI, et al. Diagnostika, lechenie i profilaktika vnebol'nichnoi pnevmonii u voennosluzhashchikh MO RF. Metodicheskie ukazaniia. Moscwa, 2010. Available at: https://studopedia.org/10-125692.html. Accessed: 12.09.2023 (in Russian).
43. Avdeev SN, Beloborodov VB, Belotserkovskiy BZ, et al. Severe community-acquired pneumonia in adults. Clinical recommendations from Russian Federation of Anaesthesiologists and Reanimatologists. Russian Journal of Anesthesiology and Reanimatology. 2022;(1):6-35 (in Russian). DOI:10.17116/anaesthesiology20220116

А.А. Зайцев*<sup>1–3

1</sup>ФГБУ «Главный военный клинический госпиталь им. акад. Н.Н. Бурденко» Минобороны России, Москва, Россия;
²ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)», Москва, Россия;
³ФГБОУ ВО «Российский университет медицины» Минздрава России, Москва, Россия
*a-zaicev-a@yandex.ru

________________________________________________

Andrey A. Zaytsev*<sup>1–3

1</sup>Burdenko Main Military Clinical Hospital, Moscow, Russia;
²BIOTECH University, Moscow, Russia;
³Russian University of Medicine, Moscow, Russia
*a-zaicev-a@yandex.ru